AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21283552 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tenofovir gel
Number of subjects: 30
Study 21283552 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study 20003839 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (2x3 g/day)
Number of subjects: 0
Study 20003839 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2x500 mg/day)
Number of subjects: 0
Study 20003839 — intervention group
Group type: COMPARATOR
Intervention: Control (Basal glucose values)
Number of subjects: 0
Study 17241504 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 50 group (bispectral index 45-55)
Number of subjects: 66
Study 17241504 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 40 group (bispectral index 35-44)
Number of subjects: 66
Study 17241504 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 15019868 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel pretreatment
Number of subjects: 79
Study 11712936 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula feeding
Number of subjects: 371
Study 11712936 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding
Number of subjects: 371
Study 10921701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (loading dose of 150 mg and maintenance dose of 0.4 mg x kg(‐1) x h(‐1) for 3 days before and 5 days after operation)
Number of subjects: 140
Study 10921701 — intervention group
Group type: COMPARATOR
Intervention: Control group (matching infusions of 5% glucose solution)
Number of subjects: 140
Study 10921701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 140
Study 10921701 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study 8748411 — intervention group
Group type: EXPERIMENTAL
Intervention: Eurocollins plus nicardipine
Number of subjects: 127
Study 8748411 — intervention group
Group type: COMPARATOR
Intervention: Eurocollins
Number of subjects: 127
Study 1433585 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management (continuous low dose antibiotic prophylaxis until vesicoureteral reflux resolved)
Number of subjects: 132
Study 1433585 — intervention group
Group type: COMPARATOR
Intervention: Surgical management (type of procedure at surgeon's discretion)
Number of subjects: 132
Study 1433585 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 132
Study 1433585 — intervention group
Group type: COMPARATOR
Intervention: Surgical management
Number of subjects: 132
Study 1433585 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 132
Study 2865943 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vitrectomy
Number of subjects: 616
Study 2865943 — intervention group
Group type: COMPARATOR
Intervention: Deferral of vitrectomy
Number of subjects: 616
Study 30540257 — intervention group
Group type: EXPERIMENTAL
Intervention: 100ms delay group
Number of subjects: 0
Study 30540257 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000ms delay group
Number of subjects: 0
Study 30540257 — intervention group
Group type: EXPERIMENTAL
Intervention: First type of near-miss configuration
Number of subjects: 0
Study 30540257 — intervention group
Group type: EXPERIMENTAL
Intervention: Second type of near-miss configuration
Number of subjects: 0
Study 30540257 — intervention group
Group type: COMPARATOR
Intervention: Delay time
Number of subjects: 0
Study 26280707 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cm pancreatic stent
Number of subjects: 240
Study 26280707 — intervention group
Group type: COMPARATOR
Intervention: 5 cm pancreatic stent
Number of subjects: 240
Study 24651160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with virgin olive oil
Number of subjects: 424
Study 24651160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 424
Study 24651160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet groups (olive oil and nuts)
Number of subjects: 424
Study 24651160 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 424
Study 22457391 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern (DP)
Number of subjects: 0
Study 20117687 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger management program for family members of patients with AUDs
Number of subjects: 63
Study 20117687 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 63
Study 18060898 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial fruit and vegetable evaluation tool
Number of subjects: 93
Study 16254743 — intervention group
Group type: EXPERIMENTAL
Intervention: Family representative payeeship
Number of subjects: 245
Study 16254743 — intervention group
Group type: EXPERIMENTAL
Intervention: Family contact
Number of subjects: 245
Study 16254743 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse
Number of subjects: 245
Study 16254743 — intervention group
Group type: EXPERIMENTAL
Intervention: History of violence
Number of subjects: 245
Study 11953190 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetramethylpyrazine (TMPZ) 4 mg/kg injected intravenously before blood collection and added to washing fluid.
Number of subjects: 60
Study 11953190 — intervention group
Group type: COMPARATOR
Intervention: Tetramethylpyrazine (TMPZ) 4 mg/kg injected intravenously before blood collection, but not added to washing fluid.
Number of subjects: 60
Study 10190648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg L-tartrate orally twice daily for 6 days
Number of subjects: 12
Study 10190648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 12
Study 10190648 — intervention group
Group type: COMPARATOR
Intervention: Debrisoquine and caffeine
Number of subjects: 12
Study 7585998 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-laser therapy
Number of subjects: 0
Study 7585998 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0
Study 1977411 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 13
Study 1977411 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 13
Study 31155160 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneled PICCs (group A)
Number of subjects: 60
Study 31155160 — intervention group
Group type: COMPARATOR
Intervention: Normal PICCs (control group)
Number of subjects: 60
Study 28993042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint manipulation
Number of subjects: 32
Study 28993042 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 32
Study 27161966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (10 mg/m²/d)
Number of subjects: 50
Study 27161966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24561814 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) - 4-6 × 30 s of all-out cycling efforts with 4-min recovery, 6 sessions within 2 weeks
Number of subjects: 26
Study 24561814 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Endurance Training (AET) - 40-60 min at 60% of peak workload, 6 sessions within 2 weeks
Number of subjects: 26
Study 24561814 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) - 6 sessions within 2 weeks
Number of subjects: 26
Study 22330085 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐γ treatment
Number of subjects: 19
Study 22330085 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U IFN‐γ in vitro
Number of subjects: 19
Study 22330085 — intervention group
Group type: COMPARATOR
Intervention: TMP‐SMX treatment
Number of subjects: 19
Study 22330085 — intervention group
Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 19
Study 21388056 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated 3-dimensional conformal radiotherapy (72 Gy in 30 fractions)
Number of subjects: 25
Study 17942817 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (12 mg per day)
Number of subjects: 14
Study 17942817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16786743 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy
Number of subjects: 22
Study 16786743 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunotherapy)
Number of subjects: 22
Study 16786743 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic rhinometry
Number of subjects: 22
Study 12598278 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL of 1% lidocaine
Number of subjects: 65
Study 12598278 — intervention group
Group type: COMPARATOR
Intervention: 1 mL of 3% lidocaine
Number of subjects: 65
Study 10375923 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy in patients with ASCUS
Number of subjects: 73
Study 10375923 — intervention group
Group type: COMPARATOR
Intervention: Control group with unsuspected cytology findings
Number of subjects: 73
Study 9049963 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade I acute GVHD
Number of subjects: 2902
Study 9049963 — intervention group
Group type: EXPERIMENTAL
Intervention: Grades II, III, IV acute GVHD
Number of subjects: 2902
Study 9049963 — intervention group
Group type: COMPARATOR
Intervention: No acute GVHD
Number of subjects: 2902
Study 9049963 — intervention group
Group type: EXPERIMENTAL
Intervention: Grades I-IV acute GVHD
Number of subjects: 2902
Study 9049963 — intervention group
Group type: EXPERIMENTAL
Intervention: Grades 0, I, II, III, IV acute GVHD
Number of subjects: 2902
Study 1996932 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exposure (two 4-min pre-exposure periods at 15 degrees/s and 30 degrees/s) followed by 16-min exposure at 60 degrees/s
Number of subjects: 45
Study 1996932 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard 16-min exposure at 60 degrees/s with no pre-exposure)
Number of subjects: 45
Study 1996932 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt exposure (two 4-min pre-exposure periods at 60 degrees/s) followed by 16-min exposure at 60 degrees/s
Number of subjects: 45
Study 6662177 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide 3 mg
Number of subjects: 8
Study 6662177 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide 6 mg
Number of subjects: 8
Study 6662177 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide 12 mg
Number of subjects: 8
Study 6662177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31796532 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and nutrition program
Number of subjects: 30
Study 31796532 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 30797255 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Number of subjects: 129
Study 30797255 — intervention group
Group type: COMPARATOR
Intervention: Sodium monofluorophosphate dentifrice
Number of subjects: 129
Study 29503163 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 2413
Study 29503163 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 2413
Study 29503163 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 2413
Study 29503163 — intervention group
Group type: EXPERIMENTAL
Intervention: General antipsychotic treatment response
Number of subjects: 2413
Study 26112815 — intervention group
Group type: COMPARATOR
Intervention: Windsurfers (N=8)
Number of subjects: 8
Study 25111080 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose ATG (sATG) 3.75 mg/kg
Number of subjects: 45
Study 25111080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose ATG (lowATG) 2.25 mg/kg
Number of subjects: 45
Study 25111080 — intervention group
Group type: COMPARATOR
Intervention: sATG
Number of subjects: 45
Study 25111080 — intervention group
Group type: EXPERIMENTAL
Intervention: lowATG
Number of subjects: 45
Study 22339146 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted eight-module HIV prevention program
Number of subjects: 812
Study 22339146 — intervention group
Group type: COMPARATOR
Intervention: General health curriculum
Number of subjects: 812
Study 19577217 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress radionuclide myocardial perfusion imaging (MPI)
Number of subjects: 400
Study 19577217 — intervention group
Group type: COMPARATOR
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 400
Study 17195144 — intervention group
Group type: EXPERIMENTAL
Intervention: Severing the umbilical cord after delivery of the anterior shoulder
Number of subjects: 60
Study 17195144 — intervention group
Group type: COMPARATOR
Intervention: Leaving the umbilical cord intact
Number of subjects: 60
Study 14872017 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (39.4 ± 4.5 mg/day)
Number of subjects: 50
Study 14872017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 14872017 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 50
Study 12487830 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl 0.9% infusion with 1 IU of heparin per milliliter
Number of subjects: 300
Study 12487830 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% infusion (control)
Number of subjects: 300
Study 10635128 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral enriched mouthrinse
Number of subjects: 0
Study 10635128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice
Number of subjects: 0
Study 10635128 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated dentifrice
Number of subjects: 0
Study 8129455 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - transdermal oestradiol (50 micrograms daily)
Number of subjects: 200
Study 8129455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 8129455 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT 'compliers' (58.4% of HRT group)
Number of subjects: 200
Study 8129455 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT 'poor-compliers' (41.6% of HRT group)
Number of subjects: 200
Study 8129455 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 200
Study 2569851 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL syrup of ipecac
Number of subjects: 10
Study 2569851 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g activated charcoal-sorbitol solution
Number of subjects: 10
Study 2569851 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 10
Study 28927890 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (10 mg two times a day)
Number of subjects: 266
Study 28927890 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (50 mg biweekly)
Number of subjects: 266
Study 27979371 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin
Number of subjects: 44
Study 27979371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 26645467 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-Plus-Statin Therapy
Number of subjects: 28
Study 26645467 — intervention group
Group type: COMPARATOR
Intervention: Diet Therapy
Number of subjects: 28
Study 26645467 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-Plus-Statin Therapy and Diet Therapy
Number of subjects: 28
Study 23070986 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.035 mg/kg body weight i.v.)
Number of subjects: 39
Study 23070986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 23070986 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 39
Study 21943218 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 37
Study 21943218 — intervention group
Group type: COMPARATOR
Intervention: 0.45% saline
Number of subjects: 37
Study 18779885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment twice daily with occlusive dressings
Number of subjects: 30
Study 18779885 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus 0.1% ointment alone
Number of subjects: 30
Study 18779885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment with occlusive dressings (hydrocolloid)
Number of subjects: 30
Study 18779885 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 30
Study 16999008 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized 0.454% stannous fluoride/sodium hexametaphosphate dentifrice
Number of subjects: 77
Study 16999008 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride control dentifrice
Number of subjects: 77
Study 11830308 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (G1)
Number of subjects: 104
Study 11830308 — intervention group
Group type: COMPARATOR
Intervention: Control group (G0)
Number of subjects: 104
Study 10738581 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV‐CFTR gene transfer
Number of subjects: 0
Study 7718250 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening invitation
Number of subjects: 282777
Study 7718250 — intervention group
Group type: COMPARATOR
Intervention: Official health statistics
Number of subjects: 282777
Study 1709958 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 53
Study 1709958 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 53
Study 7047788 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% idoxuridine in dimethyl sulfoxide
Number of subjects: 135
Study 7047788 — intervention group
Group type: COMPARATOR
Intervention: Dimethyl sulfoxide
Number of subjects: 135
Study 7047788 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 135
Study 31982030 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-based HIV self-testing
Number of subjects: 0
Study 31982030 — intervention group
Group type: COMPARATOR
Intervention: Standard provider-initiated training
Number of subjects: 0
Study 31091931 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversal temperature difference with sliding boundary condition
Number of subjects: 0
Study 31091931 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversal temperature difference with randomized boundary condition
Number of subjects: 0
Study 28192831 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+
Number of subjects: 41
Study 28192831 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmoknee
Number of subjects: 41
Study 28192831 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional warm-up)
Number of subjects: 41
Study 25040487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of Recurrence Scale (FoRSe)
Number of subjects: 169
Study 25040487 — intervention group
Group type: COMPARATOR
Intervention: Early Signs Scale (Standard)
Number of subjects: 169
Study 25040487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of Recurrence
Number of subjects: 169
Study 23328350 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity of lateral prefrontal cortex (lPFC) in adults
Number of subjects: 0
Study 23328350 — intervention group
Group type: COMPARATOR
Intervention: Functional connectivity of lateral prefrontal cortex (lPFC) in children
Number of subjects: 0
Study 21772226 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (1.0 g/kg body weight) in 250 mL of water without TVV
Number of subjects: 25
Study 21772226 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (1.0 g/kg body weight) in 250 mL of water with TVV
Number of subjects: 25
Study 21772226 — intervention group
Group type: COMPARATOR
Intervention: Sucralose (control) in 250 mL of water with or without TVV
Number of subjects: 25
Study 19521532 — intervention group
Group type: EXPERIMENTAL
Intervention: Human and bovine PZQ treatment
Number of subjects: 4
Study 19521532 — intervention group
Group type: COMPARATOR
Intervention: Human PZQ treatment only
Number of subjects: 4
Study 17143493 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (5-8 mg/kg/day)
Number of subjects: 32
Study 17143493 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT plus CPA (1 mg/kg/one day interval)
Number of subjects: 32
Study 17143493 — intervention group
Group type: COMPARATOR
Intervention: Control (no-treatment)
Number of subjects: 32
Study 15551193 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine (average dose of 131 +/- 49 mg/day)
Number of subjects: 80
Study 15551193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15551193 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 80
Study 14526301 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 75 microg every 4 hours as needed
Number of subjects: 105
Study 14526301 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 105
Study 14526301 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 105
Study 9658724 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH studies
Number of subjects: 21
Study 9658724 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cytogenetics
Number of subjects: 21
Study 9658724 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH and conventional cytogenetics
Number of subjects: 21
Study 7640146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin 75‐150 mg
Number of subjects: 18
Study 7640146 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 18
Study 7640146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2501094 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN patch (7.5 mg GTN)
Number of subjects: 16
Study 4179167 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO compatible Rh-positive pregnancy
Number of subjects: 2
Study 4179167 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO incompatible pregnancies
Number of subjects: 2
Study 31495762 — intervention group
Group type: EXPERIMENTAL
Intervention: senofilcon A lenses
Number of subjects: 43
Study 31495762 — intervention group
Group type: COMPARATOR
Intervention: lotrafilcon B lenses
Number of subjects: 43
Study 30565198 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic neurofeedback (auditory stimuli provided when concentration fell below a threshold)
Number of subjects: 33